NCT07524335RecruitingPhase 3
Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 5 Apr 2026
- Start date
- 21 Jul 2026
- Primary completion date
- 21 Jul 2027
- Lead sponsor
- Montreal Heart Institute
- Diseases
- Coronary artery disease
- NCT number
- NCT07524335
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 48
- From 21 Jul 2026 to the primary completion date, 21 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;
Other illness
- History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;
- History of significant bleeding within the past year;
- Any condition that, in the investigator's judgment, would make participation unsafe for the patient.
Age
- Severe illness with limited life expectancy (i.e., \<5 years);
Other
- Clear contraindication to aspirin;
Who the study is looking for
- Documented coronary atherosclerosis, as defined by one of the following criteria:
- Coronary artery calcium (CAC) score \> 0;
- Cardiac CT angiography (CCTA) / CoroScan: lesions \<70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \<50% in the left main coronary artery;
- Coronary angiography: lesions \<70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \<50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.
- Willing and able to provide informed consent and comply with study procedures
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montreal Heart Institute Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.